Sugi Predict

Sugi Predict / Compounds / SCHEMBL973209

SCHEMBL973209

SCHEMBL973209

NC(=O)C1C=Cc2nc3ccccc3cc2C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 1/20 0.40
▸ NPC1 O15118 5/20 0.38
▸ RAB9A P51151 5/20 0.38
▸ KMT2A Q03164 6/20 0.37
▸ ALDH1A1 P00352 5/20 0.37
▸ MEN1 O00255 5/20 0.37
▸ MAPT P10636 4/20 0.37
▸ TP53 P04637 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ GLA P06280 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ KDM4E B2RXH2 4/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7841262 0.87 RAB9A (0.39) IKBKBNPC1RAB9AKMT2AALDH1A1
SCHEMBL7094488 0.86 RAB9A (0.38) IKBKBNPC1RAB9AKMT2AALDH1A1
SCHEMBL11327657 0.83 LCK (0.35) KMT2AALDH1A1SMN1; SMN2GLAKDM4E
SCHEMBL3234460 0.82 NPC1 (0.41) IKBKBNPC1RAB9AKMT2AALDH1A1
SCHEMBL71079 0.80 NPC1 (0.41) IKBKBNPC1RAB9AKMT2AALDH1A1
SCHEMBL3735368 0.80 RAB9A (0.45) IKBKBNPC1RAB9AKMT2AALDH1A1
Hydrochloric Acid SCHEMBL1713917 0.78 NPC1 (0.41) IKBKBNPC1RAB9AKMT2AALDH1A1
SCHEMBL7088775 0.77 NPC1 (0.41) IKBKBNPC1RAB9AKMT2AALDH1A1
SCHEMBL3859298 0.77 NPC1 (0.41) NPC1RAB9AKMT2AALDH1A1MEN1
SCHEMBL9690618 0.77 NPC1 (0.41) IKBKBNPC1RAB9AKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030203910-A1 Novel compounds for enhancing chemotherapy NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-10-30 — — US claimed
WO-1999043323-A1 COMPOUNDS AND METHODS FOR CHEMOSENSITIZING MULTIDRUG RESISTANT CELLS FOX CHASE CANCER CENTER (US) 1999-09-02 — — WO claimed
WO-1997048708-A1 DENDROAMIDE COMPOUNDS AND THEIR USE IN CHEMOSENSITIZING MULTIDRUG RESISTANT CELLS FOX CHASE CANCER CENTER (US) 1997-12-24 — — WO claimed
US-20230151432-A1 KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES AMGEN INC. (US) 2023-05-18 — — US disclosed
EP-4136263-A1 KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES Amgen Inc. (US) 2023-02-22 — — EP disclosed
CN-115667551-A KIF18A inhibitors for the treatment of neoplastic diseases 美国安进公司 2023-01-31 — — CN disclosed
WO-2021211549-A1 KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES AMGEN INC. (US) 2021-10-21 — — WO disclosed
WO-2017013172-A1 NOVEL INHIBITORS OF P-GLYCOPROTEIN STICHTING KATHOLIEKE UNIVERSITEIT (NL) 2017-01-26 — — WO disclosed
US-20160244457-A1 SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT UNIV KANSAS (US) 2016-08-25 — — US disclosed
US-20150328180-A1 Composition SLOTERVAART PARTICIPATIES BV (NL) 2015-11-19 — — US disclosed
US-9089544-B2 Composition SLOTERVAART PARTICIPATIES BV (NL) 2015-07-28 — — US disclosed
WO-2001040305-A1 NOVEL ABCB9 TRANSPORTER AND USES THEREOF ACTIVE PASS PHARMACEUTICALS, INC. (CA) 2001-06-07 — — WO disclosed
WO-2001014414-A2 HUMAN ABC2 TRANSPORTER AND USES THEREOF ACTIVEPASS PHARMACEUTICALS, INC. (CA) 2001-03-01 — — WO disclosed
WO-2000024390-A9 METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS UNIV BRITISH COLUMBIA (CA) 2000-12-07 — — WO disclosed
WO-2000024390-A1 METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2000-05-04 — — WO disclosed
EP-0979086-A2 METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2000-02-16 — — EP disclosed
WO-1999043323-A1 COMPOUNDS AND METHODS FOR CHEMOSENSITIZING MULTIDRUG RESISTANT CELLS FOX CHASE CANCER CENTER (US) 1999-09-02 — — WO disclosed
US-5869650-A POTENTIATE CYTOTOXICITY OF ANTICANCER DRUGS FOX CHASE CANCER CENTER (US) 1999-02-09 — — US disclosed
WO-1998048784-A2 METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 1998-11-05 — — WO disclosed
WO-1997048708-A1 DENDROAMIDE COMPOUNDS AND THEIR USE IN CHEMOSENSITIZING MULTIDRUG RESISTANT CELLS FOX CHASE CANCER CENTER (US) 1997-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203910-A1 Novel compounds for enhancing chemotherapy ABCB1, ABCB11, ABCC1 IKBKB 2252/4885NPC1 65/4885RAB9A 873/4885
US-20230151432-A1 KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES KIF18A, KIF18B, KIF20A IKBKB 398/4885NPC1 278/4885RAB9A 724/4885
US-20160244457-A1 SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT ABCB1, ABCG2, ABCC5 IKBKB 743/4885NPC1 31/4885RAB9A 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback